Merck & Co., Inc. (MRK)
NYSE: MRK · Real-Time Price · USD
82.83
-0.36 (-0.43%)
May 5, 2025, 2:44 PM EDT - Market open
Merck & Co. Revenue
Merck & Co. had revenue of $15.53B in the quarter ending March 31, 2025, a decrease of -1.56%. This brings the company's revenue in the last twelve months to $63.92B, up 4.10% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.92B
Revenue Growth
+4.10%
P/S Ratio
3.29
Revenue / Employee
$852,293
Employees
75,000
Market Cap
207.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
| Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
| Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
| Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
| Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
| Abbott Laboratories | 42.34B |
MRK News
- 2 days ago - Dogs Of The Dow Chase May's 'Safer' Buy - Seeking Alpha
- 2 days ago - 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (May 2025) - Seeking Alpha
- 3 days ago - Top 10 High-Yield Dividend Stocks To Consider In May 2025 - Seeking Alpha
- 4 days ago - Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom - CNBC
- 5 days ago - 3 Names I Picked Up In The Latest Market Slump - Seeking Alpha
- 6 days ago - Merck to invest $1B in new US plant to make blockbuster cancer treatment Keytruda - New York Post
- 6 days ago - Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware - Business Wire
- 6 days ago - Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports - Reuters